Literature DB >> 18045117

HIV-1 neutralization: mechanisms and relevance to vaccine design.

Michael B Zwick1, Dennis R Burton.   

Abstract

Antibody (Ab) mediated neutralization is a crucial means of host resistance to many pathogens and will most likely be required in the development of a vaccine to protect against HIV-1. Here we examine mechanistic aspects of HIV-1 neutralization with attention to recent studies on the stoichiometric, kinetic and thermodynamic parameters involved. Neutralization of HIV-1, as with any microbe, minimally requires an initial molecular encounter with Ab. Ab occupancy of functional heterotrimers of the envelope glycoproteins, gp120 and gp41 (Env), indeed appears to be the dominant mechanism of neutralization for HIV-1. However, the Ab-binding site, the parameters mentioned above, as well as the stages and duration of vulnerability to Ab recognition, prior to and leading up to viral entry, each have a distinct impact on the mechanism of neutralization for any given Ab specificity. With HIV-1, the problems of mutational variation and neutralization resistance, coupled with the lability and conformational heterogeneity in Env, have stimulated the search for rational approaches to Env immunogen design that are unprecedented in vaccinology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045117     DOI: 10.2174/157016207782418443

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  31 in total

1.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

2.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

3.  Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Authors:  Daniel P Leaman; Jeong Hyun Lee; Andrew B Ward; Michael B Zwick
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Dense Array of Spikes on HIV-1 Virion Particles.

Authors:  Armando Stano; Daniel P Leaman; Arthur S Kim; Lei Zhang; Ludovic Autin; Jidnyasa Ingale; Syna K Gift; Jared Truong; Richard T Wyatt; Arthur J Olson; Michael B Zwick
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

5.  A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

Authors:  Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; Julie M Decker; Brandon F Keele; Jesus F Salazar-Gonzalez; Truman Grayson; David T McPherson; Li-Hua Ping; Jeffrey A Anderson; Ronald Swanstrom; Carolyn Williamson; George M Shaw; Beatrice H Hahn
Journal:  Virology       Date:  2009-12-08       Impact factor: 3.616

6.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

7.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

Review 8.  Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects.

Authors:  Salvador Eugenio C Caoili
Journal:  J Biomed Biotechnol       Date:  2010-03-30

9.  Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.

Authors:  Hillel Haim; Ignacio Salas; Kathleen McGee; Noah Eichelberger; Elizabeth Winter; Beatriz Pacheco; Joseph Sodroski
Journal:  Cell Host Microbe       Date:  2013-11-13       Impact factor: 21.023

10.  Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer.

Authors:  Karl Salzwedel; Edward A Berger
Journal:  Retrovirology       Date:  2009-08-11       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.